دورية أكاديمية
أعرض في EDS

Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.

التفاصيل البيبلوغرافية
العنوان: Seropositivity in blood donors and pregnant women during the first year of SARS-CoV-2 transmission in Stockholm, Sweden.
المؤلفون: Castro Dopico X; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Muschiol S; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden., Christian M; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Hanke L; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Sheward DJ; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Grinberg NF; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK., Rorbach J; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.; Max Planck Institute Biology of Ageing-Karolinska Institutet Laboratory, Karolinska Institutet, Stockholm, Sweden., Bogdanovic G; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden., Mcinerney GM; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Allander T; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden., Wallace C; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, UK.; Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK., Murrell B; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden., Albert J; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden., Karlsson Hedestam GB; From the, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
المصدر: Journal of internal medicine [J Intern Med] 2021 Sep; Vol. 290 (3), pp. 666-676. Date of Electronic Publication: 2021 May 18.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2796 (Electronic) Linking ISSN: 09546820 NLM ISO Abbreviation: J Intern Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Blackwell Scientific Publications, c1989-
مواضيع طبية MeSH: Blood Donors*, COVID-19/*epidemiology , COVID-19/*transmission , Pregnancy Complications, Infectious/*epidemiology, Adult ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19/virology ; Cross-Sectional Studies ; Female ; Humans ; Immunoglobulin G/blood ; Male ; Pandemics ; Pregnancy ; Prospective Studies ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification ; Seroepidemiologic Studies ; Spike Glycoprotein, Coronavirus/immunology ; Sweden/epidemiology ; Young Adult
مستخلص: Background: In Sweden, social restrictions to contain SARS-CoV-2 have primarily relied upon voluntary adherence to a set of recommendations. Strict lockdowns have not been enforced, potentially affecting viral dissemination. To understand the levels of past SARS-CoV-2 infection in the Stockholm population before the start of mass vaccinations, healthy blood donors and pregnant women (n = 5,100) were sampled at random between 14 March 2020 and 28 February 2021.
Methods: In this cross-sectional prospective study, otherwise-healthy blood donors (n = 2,600) and pregnant women (n = 2,500) were sampled for consecutive weeks (at four intervals) throughout the study period. Sera from all participants and a cohort of historical (negative) controls (n = 595) were screened for IgG responses against stabilized trimers of the SARS-CoV-2 spike (S) glycoprotein and the smaller receptor-binding domain (RBD). As a complement to standard analytical approaches, a probabilistic (cut-off independent) Bayesian framework that assigns likelihood of past infection was used to analyse data over time.
Setting: Healthy participant samples were randomly selected from their respective pools through Karolinska University Hospital. The study was carried out in accordance with Swedish Ethical Review Authority: registration number 2020-01807.
Participants: No participants were symptomatic at sampling, and blood donors were all over the age of 18. No additional metadata were available from the participants.
Results: Blood donors and pregnant women showed a similar seroprevalence. After a steep rise at the start of the pandemic, the seroprevalence trajectory increased steadily in approach to the winter second wave of infections, approaching 15% of all individuals surveyed by 13 December 2020. By the end of February 2021, 19% of the population tested seropositive. Notably, 96% of seropositive healthy donors screened (n = 56) developed neutralizing antibody responses at titres comparable to or higher than those observed in clinical trials of SARS-CoV-2 spike mRNA vaccination, supporting that mild infection engenders a competent B-cell response.
Conclusions: These data indicate that in the first year since the start of community transmission, seropositivity levels in metropolitan in Stockholm had reached approximately one in five persons, providing important baseline seroprevalence information prior to the start of vaccination.
(© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.)
References: Emerg Infect Dis. 2019 Oct;25(10):1868-1877. (PMID: 31423970)
N Engl J Med. 2020 Oct 29;383(18):1724-1734. (PMID: 32871063)
Lancet. 2020 Aug 1;396(10247):313-319. (PMID: 32534626)
Nat Immunol. 2021 Jan;22(1):25-31. (PMID: 33154590)
Nat Commun. 2020 Nov 12;11(1):5744. (PMID: 33184284)
Nature. 2020 Oct;586(7830):589-593. (PMID: 32785213)
PLoS One. 2020 Oct 21;15(10):e0241104. (PMID: 33085715)
Lancet Infect Dis. 2020 Jul;20(7):758-759. (PMID: 32330441)
Lancet. 2020 Jun 27;395(10242):1973-1987. (PMID: 32497510)
Science. 2020 Aug 14;369(6505):812-817. (PMID: 32434946)
Trends Immunol. 2009 Jul;30(7):313-8. (PMID: 19540810)
Emerg Infect Dis. 2007 Oct;13(10):1562-4. (PMID: 18258008)
Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Lancet Infect Dis. 2021 Feb;21(2):203-212. (PMID: 33091374)
Science. 2020 Aug 14;369(6505):818-823. (PMID: 32616673)
J Clin Microbiol. 2020 Oct 21;58(11):. (PMID: 32826322)
Nat Commun. 2020 Oct 8;11(1):5064. (PMID: 33033249)
N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912)
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. (PMID: 33221383)
Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
Nat Commun. 2020 Jul 6;11(1):3436. (PMID: 32632160)
Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674)
Cell. 2020 Aug 20;182(4):812-827.e19. (PMID: 32697968)
Nat Med. 2020 Nov;26(11):1691-1693. (PMID: 32929268)
Sci Immunol. 2020 Dec 7;5(54):. (PMID: 33288645)
Science. 2020 Nov 27;370(6520):. (PMID: 32994364)
N Engl J Med. 2021 Feb 11;384(6):533-540. (PMID: 33369366)
J Allergy Clin Immunol. 2020 Jul;146(1):35-43. (PMID: 32479758)
Sci Transl Med. 2018 Nov 14;10(467):. (PMID: 30429354)
Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513)
Euro Surveill. 2020 Jun;25(24):. (PMID: 32583766)
N Engl J Med. 2014 Jun 5;370(23):2211-8. (PMID: 24897084)
J Clin Virol. 2006 Feb;35(2):179-84. (PMID: 16112612)
Lancet. 2021 Feb 6;397(10273):452-455. (PMID: 33515491)
Nature. 2021 Mar;591(7851):639-644. (PMID: 33461210)
Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920)
Science. 2021 Jan 15;371(6526):288-292. (PMID: 33293339)
Euro Surveill. 2020 Jul;25(28):. (PMID: 32700672)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
Euro Surveill. 2021 Feb;26(5):. (PMID: 33541486)
J Intern Med. 2021 Sep;290(3):666-676. (PMID: 34008203)
Clin Infect Dis. 2020 Sep 12;71(6):1454-1460. (PMID: 32255183)
Nat Commun. 2020 Sep 4;11(1):4420. (PMID: 32887876)
Nature. 2021 Feb;590(7844):146-150. (PMID: 33142304)
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4. (PMID: 33984285)
J Clin Virol. 2021 Mar;136:104754. (PMID: 33601153)
J Gen Intern Med. 2020 Oct;35(10):3063-3066. (PMID: 32737790)
Clin Diagn Lab Immunol. 2005 Nov;12(11):1317-21. (PMID: 16275947)
Emerg Infect Dis. 2021 Jan;27(1):. (PMID: 33050983)
Emerg Infect Dis. 2006 Nov;12(11):1638-43. (PMID: 17283611)
Clin Microbiol Infect. 2021 Mar;27(3):331-340. (PMID: 33228974)
Nat Commun. 2021 Mar 22;12(1):1813. (PMID: 33753738)
Lancet Infect Dis. 2020 Oct;20(10):1151-1160. (PMID: 32559451)
N Engl J Med. 2020 Sep 10;383(11):1085-1087. (PMID: 32706954)
J Biol Rhythms. 2021 Feb;36(1):35-54. (PMID: 33491541)
Lancet. 2020 Aug 22;396(10250):535-544. (PMID: 32645347)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; MC_UP_1302/5 United Kingdom MRC_ Medical Research Council; MC_UU_00002/4 United Kingdom MRC_ Medical Research Council; WT107881 United Kingdom WT_ Wellcome Trust
فهرسة مساهمة: Keywords: COVID-19; SARS-CoV-2; Sweden; antibody testing; population immunity; serology; seroprevalence
المشرفين على المادة: 0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Immunoglobulin G)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
تواريخ الأحداث: Date Created: 20210519 Date Completed: 20210914 Latest Revision: 20240221
رمز التحديث: 20240221
مُعرف محوري في PubMed: PMC8242905
DOI: 10.1111/joim.13304
PMID: 34008203
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2796
DOI:10.1111/joim.13304